


MEDICINAL PRODUCTS 2022

NEOGEN CORP Rank 1 of 51









MEDICINAL PRODUCTS 2022

NEOGEN CORP Rank 1 of 51



The relative strengths and weaknesses of NEOGEN CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEOGEN CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points. The greatest weakness of NEOGEN CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 156%, being 169% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	591,451
Assets, Non-Current	4,496
General and Administrative Expense	378,043
Goodwill	208,247
Liabilities, Current	75,516
Liabilities, Non-Current	4,299
Other Assets	15,545
Other Compr. Net Income	8,334
Other Expenses	14,386
Other Liabilities	0
Other Net Income	1,099
Other Revenues	468,459
Property, Plant and Equipment, Net	100,453
Research and Development	16,247

Output Variable	Value in 1000 USD
Liabilities	79,815
Assets	920,192
Expenses	408,676
Revenues	468,459
Stockholders Equity	840,377
Net Income	60,882
Comprehensive Net Income	65,049
Economic Capital Ratio	156%

